HB8764, the TREAT PTSD TRICARE Act, would require the Secretary of Defense to furnish stellate ganglion block treatment to eligible members of the Armed Forces who are enrolled in TRICARE, have been diagnosed with post-traumatic stress disorder, and choose the treatment after being informed of its risks and benefits by a qualified provider. The bill applies to active-duty and reserve-component service members who have performed active service. It allows the treatment to be provided either at a Department of Defense medical facility or through a qualified provider participating in a Department-administered TRICARE health insurance program.
The bill also directs the Department of Defense to update the VA/DOD Clinical Practice Guideline for PTSD within 180 days to reflect stellate ganglion block as a therapy option and to include clinical indicators and contraindicators. The amendment to title 10 would take effect 180 days after enactment, giving the Department time to implement the new benefit and update guidance. In practical terms, the bill would add a specific PTSD treatment to military health care coverage and formalize its place in clinical guidance for service members.
HB8764 would amend chapter 55 of title 10, United States Code, by creating a new section requiring TRICARE coverage for stellate ganglion block for qualifying service members with PTSD. It would also require the Department of Defense to revise its PTSD clinical practice guideline to address the therapy and notify congressional defense committees of the update. The bill affects the Department of Defense, TRICARE administrators, military treatment facilities, participating civilian providers, and service members diagnosed with PTSD who may seek this procedure.
Based on the bill text and the absence of recorded committee debate or votes, the available context suggests a generally supportive or at least exploratory posture toward expanding PTSD treatment options for service members. The bill’s framing emphasizes access, emerging therapy, and relief for PTSD, indicating a positive intent to broaden care. However, because there are no transcripts or vote records provided, there is no documented public sentiment in the available materials beyond the bill’s sponsor-driven presentation.
The main potential points of contention are likely to involve medical evidence, clinical appropriateness, and cost or coverage implications for TRICARE and the Department of Defense. The bill requires the Secretary to furnish a specific procedure and to update clinical guidance to recognize it as an option, which may raise questions about whether the therapy is sufficiently established, which patients should receive it, and how contraindications should be defined. Any debate would likely center on whether stellate ganglion block should be mandated as a covered PTSD treatment and whether the Department should be compelled to adopt it on a fixed timeline.